Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 1.00 |
| ▸ | METAP1 | P53582 | 2/20 | 0.53 |
| ▸ | METAP2 | P50579 | 1/20 | 0.53 |
| ▸ | MASP2 | O00187 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 2/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 5/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.47 |
| ▸ | ULK1 | O75385 | 1/20 | 0.47 |
| ▸ | CDK7 | P50613 | 1/20 | 0.47 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.47 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30413155 | 1.00 | NUDT1 (1.00) | NUDT1METAP1METAP2MASP2MEN1 | |
| Water SCHEMBL31266989 | 0.98 | NUDT1 (0.96) | NUDT1METAP1METAP2MASP2MEN1 | |
| Water SCHEMBL30578580 | 0.98 | NUDT1 (0.96) | NUDT1METAP1METAP2MASP2MEN1 | |
| Ammonia Solution, Strong SCHEMBL25287071 | 0.98 | NUDT1 (0.96) | NUDT1METAP1METAP2MASP2MEN1 | |
| SCHEMBL31042611 | 0.98 | NUDT1 (0.96) | NUDT1METAP1METAP2MASP2MEN1 | |
| SCHEMBL3997824 | 0.87 | NUDT1 (0.75) | NUDT1METAP1METAP2ALDH1A1KMT2A | |
| SCHEMBL3998276 | 0.87 | NUDT1 (0.75) | NUDT1METAP1METAP2ALDH1A1KMT2A | |
| SCHEMBL483317 | 0.80 | NUDT1 (0.66) | NUDT1MASP2MEN1ALDH1A1KMT2A | |
| SCHEMBL30773469 | 0.80 | NUDT1 (0.66) | NUDT1MASP2MEN1ALDH1A1KMT2A | |
| SCHEMBL1170747 | 0.78 | METAP1 (0.72) | NUDT1METAP1METAP2PDE5AFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 791 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12463229-B2 | Bipolar ionomer membrane | CAMX POWER LLC (US) | 2025-11-04 | — | — | US | claimed |
| EP-3411430-B1 | BIPOLAR IONOMER MEMBRANE | CAMX POWER L L C (US) | 2025-08-13 | — | — | EP | claimed |
| CN-108779275-B | Bipolar ionomer membranes | 坎麦克斯动力有限责任公司 | 2024-10-15 | — | — | CN | claimed |
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | claimed |
| US-20230218521-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | UROGEN PHARMA LTD. (IL) | 2023-07-13 | — | — | US | claimed |
| US-20220352534-A1 | BIPOLAR IONOMER MEMBRANE | CAMX POWER, L.L.C. | 2022-11-03 | — | — | US | claimed |
| US-11417904-B2 | Bipolar ionomer membrane | CAMX POWER LLC (US) | 2022-08-16 | — | — | US | claimed |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-04-21 | — | — | US | claimed |
| US-10933129-B2 | Methods for administering synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte responses | SELECTA BIOSCIENCES, INC. (US) | 2021-03-02 | — | — | US | claimed |
| US-20200397695-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | UROGEN PHARMA LTD. (IL) | 2020-12-24 | — | — | US | claimed |
| US-20030185835-A1 | Adjuvant for vaccines | POWDERJECT RESEARCH LIMITED (GB) | 2003-10-02 | — | — | US | claimed |
| WO-2003080114-A2 | IMIDAZOQUINOLINE ADJUVANTS FOR VACCINES | POWDERMED LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
| WO-2003080112-A2 | IMIDAZOQUINOLINEAMINES AS ADJUVANTS IN HIV DNA VACCINATION | POWDERMED LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
| WO-2003072026-A2 | METHOD OF REDUCING AND TREATING UVB-INDUCED IMMUNOSUPPRESSION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-09-04 | — | — | WO | claimed |
| US-20030161797-A1 | Method of reducing and treating UVB-induced immunosuppression | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-28 | — | — | US | claimed |
| CN-1437463-A | System and method for treating a mucosal surface | 3M INNOVATIVE PROPERTIES CO (US) | 2003-08-20 | — | — | CN | claimed |
| WO-2003043572-A2 | METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR PATHWAYS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-05-30 | — | — | WO | claimed |
| EP-1221444-A1 | FUSED IMIDAZOLE COMPOUNDS AND REMEDIES FOR DIABETES MELLITUS | Eisai Co., Ltd. (JP) | 2002-07-10 | — | — | EP | claimed |
| US-5023256-A | Antihistamines | DOMPE FARMACEUTICI S.P.A. (IT) | 1991-06-11 | — | — | US | claimed |
| EP-0397613-A2 | Pharmacologically active aminoimidazopyridines | DOMPE' FARMACEUTICI S.p.A. (IT) | 1990-11-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218521-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | IL2, CD47, IFNG | NUDT1 3813/4885METAP1 901/4885METAP2 668/4885 |
| US-10933129-B2 | Methods for administering synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte responses | CD4, CD47, GZMB | NUDT1 2691/4885METAP1 2548/4885METAP2 2583/4885 |
| US-11773110-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | NUDT1 21/4885METAP1 2785/4885METAP2 1877/4885 |
| US-20200397695-A1 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | IL2, CD47, IFNG | NUDT1 3813/4885METAP1 901/4885METAP2 668/4885 |
| US-20030185835-A1 | Adjuvant for vaccines | TLR9, TLR3, TLR5 | NUDT1 1234/4885METAP1 2619/4885METAP2 2218/4885 |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | NUDT1 21/4885METAP1 2785/4885METAP2 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.